Background: Although hydralazine has been the drug of choice for treating pregnancy-induced hypertension for some time owing to its effect on peripheral vascular tonus, its effects on utero- and feto-placental circulation are less well understood.
Methods: To evaluate the effect of hydralazine on placental circulation in cases of pre-eclampsia, Doppler ultrasonography was used to record blood velocity in the arcuate and umbilical arteries in 12 pregnancies complicated by pre-eclampsia, blood velocity in the maternal renal artery also being examined. The gravidae underwent Doppler ultrasonography after 24 hours bedrest in hospital (baseline values), and again 24 and 72 hours after starting oral hydralazine treatment at doses of 50 mg twice daily.
Results: The gravidae showed increased heart rate and decreased blood pressure in response to treatment, but neither placental nor maternal renal blood velocity waveforms were affected.
Conclusion: The results suggest that at recommended oral doses hydralazine has no effect on placental or maternal renal vascular resistance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00016349509024401 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative efficacy and safety between intravenous labetalol and intravenous hydralazine for hypertensive disorders in pregnancy: A systematic review and meta-analysis of 19 randomized controlled trials.
Eur J Obstet Gynecol Reprod Biol
December 2024
Federal University of Roraima, Boa Vista, Roraima, Brazil.
Article Synopsis
- Hypertensive disorders in pregnancy can lead to serious complications, prompting the need for medication such as hydralazine and labetalol to lower blood pressure.
- A systematic review of 19 randomized controlled trials compared the effectiveness and safety of intravenous labetalol versus hydralazine in managing these conditions.
- The findings indicated no significant differences in blood pressure outcomes between the two medications, but labetalol was found to significantly reduce instances of maternal hypotension compared to hydralazine.
GPER Stimulation Attenuates Cardiac Dysfunction in a Rat Model of Preeclampsia.
Hypertension
November 2024
Department of Biomedical Engineering (A.K.N.d.A., S.M., C.L.B.), Tulane University, New Orleans, LA.
Article Synopsis
- Preeclampsia is a serious condition during pregnancy that causes high blood pressure and heart problems for both mothers and their babies.
- Scientists tested a drug called G-1 to see if it could help with these issues in a rat model of preeclampsia.
- The results showed that G-1 lowered blood pressure and improved heart function, while another drug only lowered blood pressure without helping the heart.
The vasodilator effect of Eugenol on uterine artery - potential therapeutic applications in pregnancy-associated hypertension.
J Recept Signal Transduct Res
April 2024
Department of Pharmacology & Toxicology, College of Veterinary Science and Animal Husbandry, Orissa University of Agriculture and Technology, Bhubaneswar, India.
Preeclampsia, a gestational associated hypertension, has been reported in 6-8% of pregnant women worldwide leading to premature delivery and low birth weight of newborn due to reduced blood flow to placenta. Although several vasodilators (Methyl dopa, hydralazine, β-blockers and diuretics) are currently in use to treat preeclampsia, still there is a search for safer drugs with better efficacy. Lately, antihypertensive vasodilators from natural sources are gaining importance in treating preeclampsia.
View Article and Find Full Text PDFFibroblast Growth Factor Type 2 (FGF2) Administration Attenuated the Clinical Manifestations of Preeclampsia in a Murine Model Induced by L-NAME.
Front Pharmacol
April 2021
Molecular Medicine Laboratory, Unidad Academica de Medicina Humana y C.S, Universidad Autonoma de Zacatecas, Zacatecas, Mexico.
In preeclampsia, a hypertensive disorder of pregnancy, the poor remodeling of spiral arteries leads to placental hypoperfusion and ischemia, provoking generalized maternal endothelial dysfunction and, in severe cases, death. Endothelial and placental remodeling is important for correct pregnancy evolution and is mediated by cytokines and growth factors such as fibroblast growth factor type 2 (FGF2). In this study, we evaluated the effect of human recombinant FGF2 (rhFGF2) administration in a murine model of PE induced by NG-nitro-L-arginine methyl ester (L-NAME) to test if rhFGF2 administration can lessen the clinical manifestations of PE.
View Article and Find Full Text PDFPrevalence of Eclampsia and Its Maternal-Fetal Outcomes at Gandhi Memorial Hospital, Addis Ababa Ethiopia, 2019: Retrospective Study.
Int J Womens Health
February 2021
Department of Midwifery, College of Health Science and Medicine, Wolaita Sodo University, Wolaita Sodo, Ethiopia.
Background: Eclamptic disorder during pregnancy is one of the common problems in sub-Saharan countries and forms one of the deadly triads along with hemorrhage and infection which complicates feto-maternal outcomes of pregnancy. So, the purpose of this study was to assess the prevalence of eclampsia and its maternal and fetal outcome in Gandhi Memorial Hospital, Addis Ababa Ethiopia, 2019.
Methods: A descriptive retrospective cross-sectional study was employed on a review of all cases of women who were delivered at Gandhi memorial Hospital from 1st of September 2017 to -last of August 2018.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!